List of Excipients in Branded Drug NUZYRA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Paratek Pharmaceuticals Inc	NUZYRA	omadacycline	71715-001	HYDROCHLORIC ACID	2031-03-18
Paratek Pharmaceuticals Inc	NUZYRA	omadacycline	71715-001	SODIUM HYDROXIDE	2031-03-18
Paratek Pharmaceuticals Inc	NUZYRA	omadacycline	71715-001	SUCROSE	2031-03-18

NUZYRA Excipient Strategy and Commercial Opportunities for Omadacycline

Last updated: September 3, 2026

NUZYRA, the brand name for omadacycline, uses a relatively simple oral-tablet and intravenous formulation platform. Its main excipient constraint is pharmacokinetic: as a tetracycline-class antibiotic, omadacycline can interact with polyvalent cations, including calcium, magnesium, aluminum and iron. The strongest commercial opportunities are differentiated oral formulations, pediatric-friendly dosage forms, hospital-ready intravenous presentations, excipient supply, and intellectual property focused on administration, stability, and drug-excipient compatibility.

NUZYRA was approved by the U.S. Food and Drug Administration in 2018 for adults with community-acquired bacterial pneumonia and acute bacterial skin and skin-structure infections.[1] Paratek Pharmaceuticals developed the product. The active ingredient is omadacycline, administered as omadacycline tosylate.

What excipients are used in NUZYRA tablets and injection?

NUZYRA tablets use conventional solid-dose excipients for compression, disintegration, lubrication and film coating. The injectable product uses a low-complexity lyophilized or sterile powder formulation designed for reconstitution before intravenous infusion.

Dosage form	Strength	Principal labeled excipients or formulation components	Commercial function
Oral tablet	150 mg	Microcrystalline cellulose, croscarmellose sodium, magnesium stearate, hypromellose, titanium dioxide, triacetin, yellow iron oxide	Compression, disintegration, lubrication, film coating and color
Intravenous injection	100 mg/vial	Mannitol, meglumine, hydrochloric acid and sodium hydroxide	Bulking, pH control and solubilization
Active pharmaceutical ingredient	Equivalent to omadacycline	Omadacycline tosylate	Antibacterial active

The precise manufacturing formula may include process controls and material grades that are not fully disclosed in the prescribing information. FDA labeling identifies the excipient classes and named ingredients, but not every formulation parameter or supplier specification.[2]

Oral-tablet formulation design

Microcrystalline cellulose provides tablet structure and improves compactability. Croscarmellose sodium supports rapid tablet breakup. Magnesium stearate reduces tooling friction, although excessive lubrication can affect tablet dissolution and content uniformity.

The film coat provides protection from handling, improves swallowability and supports product identification. Hypromellose is the primary film-forming polymer. Titanium dioxide and yellow iron oxide provide opacity and color. Triacetin acts as a plasticizer.

The formulation is commercially conventional. That lowers manufacturing complexity but also limits differentiation based solely on the existing excipient platform. A follow-on product would need to create value through pharmacokinetic performance, patient convenience, stability, taste, dose flexibility or reduced food and mineral interaction.

Intravenous formulation design

Mannitol is commonly used as a bulking agent and tonicity modifier in sterile products. Meglumine can improve solubility and contribute to pH control. Hydrochloric acid and sodium hydroxide provide final pH adjustment.

The commercial value of the injectable formulation is tied less to excipient novelty than to sterile manufacturing, reconstitution time, particulate control, container closure integrity, compatibility and hospital workflow.

Why are mineral interactions the central excipient issue for NUZYRA?

Omadacycline belongs to the tetracycline class, where chelation with polyvalent cations is a known administration risk. Calcium, magnesium, aluminum and iron can reduce absorption when administered close to oral omadacycline dosing.[1]

This creates an excipient-screening requirement. Formulators must assess:

• Calcium or magnesium in nutritional products.
• Iron in supplements and combination medicines.
• Aluminum- or magnesium-containing antacids.
• Mineral-fortified beverages and oral nutrition products.
• Cation-containing buffering systems.
• Packaging components or process-contact materials that could contribute extractables or leachables.

The issue is not limited to inactive ingredients inside the tablet. It affects co-packaged products, dosing instructions, patient-support materials and potential combination products.

A differentiated formulation could target less restrictive administration with food or mineral-containing products. That claim would require comparative pharmacokinetic evidence and may support new method-of-use or formulation patent filings if the resulting product has a measurable clinical or technical advantage.

What commercial excipient opportunities exist for NUZYRA?

The largest opportunity is not replacing every current excipient. It is solving a specific product constraint while preserving omadacycline exposure and manufacturability.

1. Mineral-tolerant oral formulations

A reformulated tablet, capsule, multiparticulate product or amorphous solid dispersion could seek to reduce the effect of dietary minerals or antacids on absorption.

Potential technical approaches include:

• Polymer matrices that control local drug release.
• Enteric or delayed-release coatings.
• Amorphous dispersions using polymers such as hypromellose acetate succinate or copovidone.
• Lipid-based systems.
• Cyclodextrin or ion-pairing approaches.
• Multiparticulates with separate drug and excipient domains.
• Immediate-release systems with enhanced dissolution and reduced precipitation.

The commercial opportunity depends on showing that the formulation improves a clinically relevant administration limitation. A formulation that merely changes excipients without improving exposure, stability or usability would have limited market protection.

2. Pediatric and geriatric dosage forms

NUZYRA is an adult product. A pediatric formulation could create a separate product opportunity if regulatory development supports a pediatric indication or age expansion.

Potential formats include:

• Oral suspension.
• Powder for reconstitution.
• Dispersible tablet.
• Mini-tablet.
• Granules or sachets.
• Taste-masked oral liquid.

Taste masking is important because tetracycline-class compounds can have strong bitterness. Suitable systems may include polymeric taste barriers, ion-exchange resins, lipid coatings or multiparticulate encapsulation.

A pediatric product would need to manage mineral interactions in milk, fortified foods and pediatric nutritional products. Dose flexibility, reconstitution stability and microbial preservation would also become central development issues.

3. Hospital-ready intravenous presentations

The injectable product creates opportunities for hospital efficiency rather than consumer-facing differentiation. Potential improvements include:

• Ready-to-use premixed bags.
• Dual-chamber or closed-system reconstitution devices.
• Reduced reconstitution time.
• Smaller vial or bag configurations.
• Improved stability after reconstitution.
• Compatibility with common infusion materials.
• Barcoded unit-dose packaging.
• Reduced preparation steps for antimicrobial stewardship programs.

These improvements can support hospital formulary adoption even when the active ingredient and labeled indication remain unchanged.

4. Excipient and material supply

The current formulation uses high-volume pharmaceutical excipients with established supplier markets. Commercial opportunities exist in:

• Direct supply of compendial-grade mannitol.
• Low-peroxide microcrystalline cellulose.
• Controlled-particle-size croscarmellose sodium.
• Low-metal or low-elemental-impurity excipient grades.
• Sterile-grade meglumine.
• Film-coating systems.
• Ready-to-use coating premixes.
• Container-closure systems for sterile injection.
• Single-use reconstitution and transfer devices.

Supplier qualification is a significant barrier. A change in excipient source can trigger comparability work, process validation, stability studies and regulatory documentation. For a commercially established product, a supplier that reduces batch variability or improves supply security can have more value than a lower-cost commodity source.

What formulations are protected by NUZYRA intellectual property?

Omadacycline’s intellectual property can be divided into four broad categories:

1. Composition-of-matter protection for omadacycline or related tetracycline derivatives.
2. Formulation protection covering salts, solid forms, dosage forms or excipient systems.
3. Method-of-use protection covering approved antibacterial indications or dosing regimens.
4. Manufacturing protection covering synthesis, purification, crystallization or impurity control.

Public FDA materials identify NUZYRA as a drug-device and formulation product with Orange Book-listed patent information, but the commercial relevance of each patent depends on claim scope, terminal disclaimers, patent-term adjustment, patent-term extension, prosecution history and litigation posture.[3]

For excipient companies, the most relevant claims are formulation and manufacturing claims. A supplier may avoid direct infringement by selling a broadly used excipient, but risk can arise when it markets a proprietary combination, premix, coated particle, drug-excipient complex or ready-to-use formulation specifically directed to omadacycline.

Patent diligence priorities

A NUZYRA excipient program should review:

• U.S. Orange Book listings.
• Patent claims directed to oral or injectable dosage forms.
• Continuation and divisional applications.
• Patent-term adjustment and patent-term extension.
• Foreign counterparts in Europe, Canada, Japan and other commercial markets.
• Claim language covering salts, polymorphs, particle size, dissolution and stability.
• Method-of-treatment claims tied to dosing schedules.
• Freedom-to-operate risks for pediatric, long-acting and mineral-tolerant products.

A formulation patent that claims a narrow excipient ratio may provide useful protection but can be vulnerable to design-around. A patent covering a demonstrated pharmacokinetic advantage, defined dissolution profile or broad delivery architecture is usually more valuable.

When does NUZYRA lose exclusivity and when can generics enter?

NUZYRA has several distinct exclusivity layers:

Exclusivity or barrier	Relevance
FDA new chemical entity exclusivity	Initially delayed abbreviated new drug application submission for five years from approval, subject to statutory exceptions
Orange Book patents	May block approval or commercial launch depending on expiration and litigation
Pediatric exclusivity	Can add six months if qualifying studies and statutory requirements are completed
Formulation and method-of-use patents	May protect specific products, uses or delivery systems after core composition claims expire
Regulatory and manufacturing know-how	Can delay practical competition even after formal patent expiry

A generic applicant may submit an ANDA with a Paragraph IV certification against an unexpired listed patent. The patent holder can then sue within the statutory period, triggering a potential 30-month stay of approval under the Hatch-Waxman framework.[4]

A Paragraph IV filing does not itself establish that a generic can launch. The timing depends on patent expiration, litigation outcomes, settlement terms, regulatory approval and any applicable pediatric extension.

Because the product is a small-molecule antibiotic, biosimilar regulation does not apply. Competition would proceed through the ANDA pathway, not the 351(k) biosimilar pathway.

What is the Orange Book status of NUZYRA?

NUZYRA is subject to FDA Orange Book listing because it is an approved small-molecule drug. The Orange Book can list patents covering the drug substance, drug product or approved method of use.[3]

For commercial diligence, the key questions are:

• Which patents are currently listed?
• Which claims cover the approved tablet or injection?
• Which listed patents expire first?
• Are any patents subject to pediatric exclusivity?
• Have Paragraph IV notices been filed?
• Has the sponsor initiated infringement litigation?
• Are there settlements restricting the timing of generic entry?
• Do listed patents cover only methods of use that can be carved out of an ANDA label?

A method-of-use patent may be less effective than a product patent if the generic can omit the protected indication from its label. A drug-product patent covering the tablet composition, dosage form or injectable presentation usually creates a more direct barrier.

Which companies are challenging NUZYRA exclusivity?

Publicly available commercial and regulatory information should be reviewed for current ANDA filings, Paragraph IV notices and Hatch-Waxman litigation. The relevant challenger set may include large generic manufacturers, specialty generic companies and contract development partners.

The absence of a widely publicized challenge does not eliminate risk. Generic applicants can file confidentially until required notice is provided, and patent litigation may emerge close to the expected launch window.

The most credible generic launch scenarios are:

At-risk launch

A generic launches before all patent disputes are resolved. This can create damages exposure, injunction risk and rapid price erosion.

Negotiated entry

The sponsor settles litigation and permits entry on a specified date, often before the latest patent expiration. Settlement terms may include restrictions on launch timing, authorized generic arrangements or manufacturing limitations.

Label carve-out

The generic omits a patented method of use but retains nonprotected indications. This scenario is more feasible when the remaining indication supports commercially viable volume.

Post-patent launch

The generic waits for all meaningful product patents to expire. This produces the lowest litigation risk but may leave substantial value on the table if market entry is delayed.

How strong is the NUZYRA patent estate for excipient-based products?

The estate is strongest where an excipient or delivery feature produces a measurable product attribute. Examples include:

• Improved oral bioavailability in the presence of minerals.
• Defined dissolution under fed and fasted conditions.
• Improved reconstitution stability.
• Reduced particulate formation.
• Extended post-reconstitution stability.
• A specific solid form or particle-size distribution.
• A pediatric dosage form with validated taste masking.
• A ready-to-use intravenous presentation with defined storage conditions.

The estate is weaker when claims cover routine excipient substitution without an unexpected result. Replacing one standard filler with another, changing a coating color or using a conventional lubricant is unlikely to create durable exclusivity unless the change produces a non-obvious technical benefit.

A strong filing strategy would combine composition claims, process claims, performance claims and use claims. The claims should cover the product as manufactured, the excipient architecture and the measurable benefit.

How does NUZYRA compare with competing antibiotics?

NUZYRA competes with other agents used for community-acquired pneumonia and skin infections, including doxycycline, minocycline, omadacycline alternatives, fluoroquinolones, macrolides, beta-lactams and newer branded antibiotics.

Product type	Excipient opportunity	Main commercial constraint
Generic doxycycline	Low-cost tablets, capsules and suspensions	High generic competition
Generic minocycline	Modified-release and tolerability formulations	Established low-cost supply
NUZYRA	Mineral-tolerant, pediatric and hospital-ready formulations	Higher branded-product cost and administration restrictions
New branded antibiotics	Novel delivery systems and dosing	Smaller target markets and reimbursement pressure

NUZYRA’s differentiation is based on its aminomethylcycline structure and activity profile, not on a highly complex excipient system. That leaves room for lifecycle products that improve administration, adherence and hospital logistics without changing the active antibacterial mechanism.

What FDA regulatory pathway applies to a new NUZYRA formulation?

A materially different formulation would generally require a supplemental new drug application if developed by the innovator, or an ANDA, 505(b)(2) application or other pathway depending on the sponsor’s relationship to the reference product and the extent of formulation change.[5]

The regulatory package may need:

• Comparative bioavailability data.
• Fed and fasted pharmacokinetic studies.
• Mineral-interaction studies.
• Dissolution and in vitro release data.
• Stability data.
• Extractables and leachables data for new packaging.
• Container-closure integrity testing.
• Microbiological and preservative studies for liquids.
• Compatibility studies for intravenous administration.
• New clinical data if the formulation changes exposure or use conditions.

An excipient with prior FDA use may reduce toxicology requirements, but it does not remove the need to demonstrate product quality and bioequivalence where applicable.

What revenue exposure is linked to NUZYRA formulation risk?

NUZYRA revenue is exposed to four formulation-related risks:

1. Generic tablet entry and price erosion.
2. Hospital substitution toward competing intravenous antibiotics.
3. Patient nonadherence caused by mineral and food administration restrictions.
4. Loss of differentiation if competitors offer easier dosing or pediatric formats.

The most valuable lifecycle strategy is likely an oral formulation that improves administration without reducing exposure. A second priority is an intravenous presentation that lowers hospital preparation burden. Pediatric development could expand the addressable population but would require greater clinical, regulatory and commercial investment.

Key Takeaways

• NUZYRA uses conventional tablet excipients and a relatively simple intravenous excipient system.
• Mineral and metal interactions are the central formulation constraint for oral omadacycline.
• The strongest commercial opportunity is a mineral-tolerant or otherwise administration-flexible oral formulation.
• Pediatric dispersible, suspension and taste-masked products could create lifecycle value.
• Ready-to-use intravenous presentations could improve hospital adoption and reduce preparation errors.
• Excipient suppliers can compete through low-metal grades, tighter particle-size control, sterile materials and supply reliability.
• Small-molecule generic competition would proceed through the ANDA and Paragraph IV framework.
• Biosimilar competition does not apply to NUZYRA.
• Excipient-based patent claims are strongest when linked to measurable pharmacokinetic, stability, dissolution or administration benefits.
• Current Orange Book listings, patent expiration dates, Paragraph IV notices and settlement terms must be tracked before making a launch or licensing decision.

FAQs About NUZYRA Excipients and Commercial Opportunities

Can NUZYRA be reformulated as an oral suspension?

Yes. An oral suspension could improve dose flexibility and pediatric usability, but it would require taste masking, physical stability, microbial control, redispersibility and mineral-interaction testing.

Which excipient most directly affects NUZYRA tablet performance?

Croscarmellose sodium is important for disintegration, while magnesium stearate can affect wetting and dissolution if overused. Microcrystalline cellulose controls tablet compactability and mechanical strength.

Can calcium be included in a NUZYRA formulation?

Calcium is a formulation risk because it can chelate tetracycline-class compounds. Any calcium-containing formulation would require evidence that the calcium does not reduce omadacycline exposure or product performance.

Is a generic NUZYRA likely to use the same excipients?

A generic may use different excipients if it meets quality, bioequivalence, safety and labeling requirements. The generic must manage the same mineral-interaction and dissolution risks even if its excipient list differs.

What is the best licensing target around NUZYRA?

The most attractive targets are technologies that improve oral exposure in the presence of minerals, enable pediatric dosing, extend post-reconstitution stability or convert the injectable product into a ready-to-use hospital presentation.

References

1. U.S. Food and Drug Administration. (2018). NUZYRA (omadacycline) prescribing information.
2. DailyMed. (n.d.). NUZYRA- omadacycline tosylate tablet and NUZYRA- omadacycline tosylate injection. U.S. National Library of Medicine.
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application submissions and Paragraph IV certifications.
5. U.S. Food and Drug Administration. (2023). Applications covered by section 505(b)(2).